Anders Jacobson
Director/Board Member chez KLARIA PHARMA HOLDING AB
Fortune : 6 378 $ au 31/03/2024
Profil
Anders Jacobson is currently the Deputy Chairman at MD Biomedical AB.
He is also an Independent Director at Klaria Pharma Holding AB and the Chief Innovation Officer at Senzime AB.
Previously, he served as a Director at Acarix AB from 2020 to 2021.
Mr. Jacobson holds a graduate degree from the University of Uppsala.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SENZIME AB
0,01% | 30/12/2022 | 11 000 ( 0,01% ) | 6 378 $ | 31/03/2024 |
Postes actifs de Anders Jacobson
| Sociétés | Poste | Début |
|---|---|---|
| SENZIME AB | Corporate Officer/Principal | 01/02/2022 |
| KLARIA PHARMA HOLDING AB | Director/Board Member | 01/01/2022 |
MD Biomedical AB
 MD Biomedical AB Medical/Nursing ServicesHealth Services Part of Senzime AB, MD Biomedical AB provides micro dialysis products and services. The private company is based in Umeå, Sweden. The Swedish company was founded in 2011 by Pernilla Abrahamsson. MD Biomedical was acquired by Senzime AB on April 21, 2015 for $0.24 million. | Director/Board Member | - |
Anciens postes connus de Anders Jacobson
| Sociétés | Poste | Fin |
|---|---|---|
| ACARIX AB | Director/Board Member | 11/05/2021 |
Formation de Anders Jacobson
| University of Uppsala | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SENZIME AB | Health Technology |
| ACARIX AB | Health Technology |
| KLARIA PHARMA HOLDING AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
MD Biomedical AB
MD Biomedical AB Medical/Nursing ServicesHealth Services Part of Senzime AB, MD Biomedical AB provides micro dialysis products and services. The private company is based in Umeå, Sweden. The Swedish company was founded in 2011 by Pernilla Abrahamsson. MD Biomedical was acquired by Senzime AB on April 21, 2015 for $0.24 million. | Health Services |
